Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
LITESPARK-005
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
- NCT04195750 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Deep
We haven't built an HCP commentary report on LITESPARK-005 (belzutifan) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LITESPARK-005 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 106 | |
| Podcasts | 25 | |
| YouTube | 23 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Belzutifan; Everolimus
- Arms
- Belzutifan · Experimental
- Everolimus · Active comparator
- Safety Run-In · Experimental
- Enrollment
- 755
- Primary outcomes
- Progression-free Survival (PFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Feb 27, 2020
- Primary completion
- Apr 15, 2024
- Results posted
- Yes
- Registry record
- NCT04195750 · updated Oct 20, 2026
Publications
linked from the registry- Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gumus M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Manneh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B; LITESPARK-005 Investigators. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024 Aug 22;391(8):710-721. doi: 10.1056/NEJMoa2313906. PubMed 39167807
- Powles T, Choueiri TK, Albiges L, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gumus M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Rizzo M, Shinde R, Saretsky TL, He L, Perini RF, Vickery D, Rini B. Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Apr;26(4):491-502. doi: 10.1016/S1470-2045(25)00032-4. Epub 2025 Mar 17. PubMed 40112850